ProCE Banner Activity


Treating Gynecologic Cancers: Current Approaches to Patient Care

PCE On Demand Live Presentation

In this video lecture, a seasoned gynecologic oncologist discusses strategies for optimizing the use of novel and emerging therapies for advanced gynecologic cancers, including PARP inhibitor therapy for ovarian cancer, immunotherapies in endometrial cancer, and individualizing therapy decisions and managing adverse events of novel therapies in cervical cancer.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: December 27, 2022

Expiration: December 26, 2023

No longer available for credit.



David Scott Miller

David Scott Miller, MD, FACOG, FACS

Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Direct and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas

Terran W. Sims

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Nurse Practitioner
Department of Urology
University of Virginia
Charlottesville, Virginia

Provided by

ProCE Banner


Supported by educational grants from



Seagen and Genmab

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Formulate evidence-based strategies for the use of novel therapies in patients with gynecologic cancers

  • Use recommended approaches to manage toxicities associated with innovative treatments for endometrial, ovarian, and cervical cancers 

  • Integrate patient education and feedback to optimize patient experiences during treatment and survivorship


All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

David Scott Miller, MD, FACOG, FACS: researcher: Advaxis, Advenchen, Aeterna Zentaris, Agenus, Akesobio, Aprea AB, AstraZeneca, EMD Serono, Immunogen, Incyte, Janssen, Karyopharm, Leap Therapeutics, Mateon, Merck Sharp & Dohme, Millennium, Novartis, NVision, Regeneron, Syros, Tesaro, Tracon, US Biotest, Xenetic Biosciences; consultant: AbbVie, Agenus, Alexion, AstraZeneca, Asymmetric Therapeutics, Boston Biomedical Research Institute, Clovis Oncology, Eisai, Eisai Europe, EMD Serono, Genentech, GlaxoSmithKline, Guardant Health, Immunogen, Incyte, iTeso Belgium, Janssen Oncology, Karyopharm, Merck Sharp & Dohme, Myriad Genetics, Novocure, Seagen, Tarveda Therapeutics, Tesaro.

Terran Sims, MSN, ACNP-C, CNN, COCN-C: consultant/advisor/speaker: Cololast Corp.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange have no relevant financial relationships to disclose.

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form 

The estimated time to complete this activity is 1.00 hour.

Release date: December 27, 2022
Expiration date: December 26, 2022


This program has been made available online.


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education, Practicing Clinicians Exchange, or any educational supporter.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit.


AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until December 26, 2023. PAs should only claim credit commensurate with the extent of their participation.


IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.